Complete Guide to Switching Between Weight Management Treatments
Understanding Wegovy and Mounjaro Equivalent Doses for Treatment Switching
When considering switching between Wegovy and Mounjaro, understanding equivalent doses requires clinical expertise rather than direct mathematical conversion. Wegovy (semaglutide) operates as a GLP-1 receptor agonist, whilst Mounjaro (tirzepatide) functions as a dual GIP and GLP-1 receptor agonist, creating different therapeutic profiles despite similar appetite-regulating effects. Your prescriber will assess your current dose, treatment response, and individual factors to determine the most appropriate equivalent starting dose. This personalised approach ensures treatment continuity whilst minimising potential side effects during transition.
The concept of equivalent doses between these treatments involves evaluating therapeutic effect rather than milligram-to-milligram comparison. Clinical experience suggests that patients switching from Mounjaro maintenance doses may start Wegovy at intermediate rather than starter doses, though individual responses vary significantly. EverydayMeds' clinical team collaborates with prescribers to ensure smooth transitions, considering your treatment history and goals. Both treatments require the same lifestyle modifications - reduced-calorie diet and increased physical activity - maintaining consistency in your weight management approach regardless of which medication you choose.
Wegovy and Mounjaro Pricing Comparison: Switch & Save Opportunities
Comparing costs between Wegovy and Mounjaro equivalent doses reveals significant savings opportunities for patients considering treatment switches. Wegovy pricing at EverydayMeds starts from £79.99 for 0.25mg starter doses, progressing through £94.99 (0.5mg), £99.99 (1mg), £139.99 (1.7mg), to £209.99 for 2.4mg maintenance doses. New customers apply discount code FIRST40 at checkout, whilst returning customers use DOSE25 to reach these final prices. Our bundle options provide additional convenience, including the Intro Trio (0.25mg, 0.5mg, 1mg) for £299.99, supporting complete dose escalation in one order.
The financial advantage of switching becomes apparent when comparing monthly maintenance costs between treatments. Our Consistency bundles offer two-month supplies: Consistency 1mg (×2) for £209.99, Consistency 1.7mg (×2) for £309.99, and Consistency 2.4mg (×2) for £419.99. For patients requiring extended supply security, the Ultimate Stability Trio provides three months of 2.4mg maintenance doses for £649.99. These pricing structures often represent substantial savings compared to alternative treatments, particularly for long-term weight management commitments. The GPhC-registered pharmacy status (#9012878) ensures quality assurance whilst maintaining competitive pricing.
Clinical Evidence Supporting Wegovy and Mounjaro Equivalent Therapeutic Effects
Clinical trials demonstrate both treatments' efficacy in weight management, though direct comparison of Wegovy and Mounjaro equivalent doses comes from separate study programs. The STEP trials showed Wegovy patients achieved approximately 15% average weight loss at 68 weeks when combined with lifestyle modifications, as reported by Wilding et al., NEJM, 2021. The STEP 2 trial specifically examined patients with type 2 diabetes, showing 9.6% average weight loss, whilst STEP 5 demonstrated sustained clinically studied weight loss maintained at two years.
Mounjaro's SURMOUNT trials revealed impressive weight loss outcomes, though comparing percentages directly between trials isn't clinically appropriate due to different study designs and populations. Both treatments function through appetite regulation and satiety enhancement, supporting similar therapeutic goals despite different receptor mechanisms. The SELECT cardiovascular outcomes trial demonstrated Wegovy's additional benefit in reducing major cardiovascular events by 20% in eligible patients. These evidence bases support both treatments as effective options, with prescriber guidance essential for determining individual suitability.
How Wegovy Works: GLP-1 Mechanism in Equivalent Dose Planning
Wegovy functions as a GLP-1 receptor agonist, mimicking the action of natural incretin hormones that regulate appetite and glucose metabolism. When administered weekly via subcutaneous injection, semaglutide binds to GLP-1 receptors in the brain's appetite control centres, promoting feelings of fullness and reducing food cravings. This mechanism explains why Wegovy and Mounjaro equivalent doses produce similar satiety effects, despite targeting slightly different receptor pathways. The medication slows gastric emptying, extending the feeling of fullness after smaller meals, whilst simultaneously influencing neural pathways that control food-seeking behaviour. Understanding this mechanism helps patients appreciate why gradual dose escalation is essential - allowing the body to adjust to increasing receptor activation whilst minimising gastrointestinal side effects.
EverydayMeds Ordering Process for Wegovy and Mounjaro Equivalent Doses
Accessing Wegovy through EverydayMeds begins with our streamlined 3-minute online clinical assessment, designed to capture essential medical history and treatment goals efficiently. Our qualified prescribers review each application within 3 working days as standard, with express 24-hour review available for urgent cases including treatment switches. The assessment considers your current medication regimen, previous treatment responses, and individual health factors to determine appropriate Wegovy and Mounjaro equivalent doses if switching. Once approved, we dispatch your prescription-only medicine via next-day delivery using temperature-controlled cold-chain logistics to maintain medication integrity. Our GPhC-registered pharmacy status (#9012878) ensures all dispensing meets stringent UK regulatory standards whilst providing the convenience of direct-to-door delivery.
Storage and Practical Considerations for Wegovy and Mounjaro Dose Transitions
Wegovy storage requirements offer practical advantages during treatment transitions, particularly for patients switching from Mounjaro. Pre-use storage requires refrigeration at 2-8°C, but once removed from the fridge, Wegovy maintains stability for up to 6 weeks at room temperature below 30°C - significantly longer than Mounjaro's 21-day room temperature limit. The FlexTouch pen design provides consistent, precise dosing throughout the mandatory escalation schedule: 0.25mg (weeks 1-4), 0.5mg (weeks 5-8), 1mg (weeks 9-12), 1.7mg (weeks 13-16), and 2.4mg maintenance from week 17 onwards. This structured progression cannot be accelerated, ensuring patient safety whilst building treatment tolerance. The extended room temperature stability particularly benefits patients with active lifestyles or frequent travel commitments.
Personalised Switching Strategies for Wegovy and Mounjaro Equivalent Doses
Successful transitions between weight management treatments require individualised approaches that consider multiple factors beyond simple dose equivalence. Patients switching from Mounjaro to Wegovy may experience different side effect profiles due to the single versus dual receptor targeting, potentially requiring adjusted starting doses or modified escalation timelines. Some patients switch due to injection site reactions, gastrointestinal tolerance, or insurance coverage changes, whilst others seek the cardiovascular benefits demonstrated in Wegovy's SELECT trial. EverydayMeds facilitates these transitions by maintaining detailed treatment records and coordinating with prescribers to ensure continuity of care.
The timing of treatment switches requires careful consideration of current dose stability and treatment response patterns. Patients well-established on maintenance doses may transition more smoothly than those still escalating, though individual responses vary significantly. Our clinical team provides guidance on managing the transition period, including strategies for minimising disruption to weight loss progress and managing any temporary side effect differences. This personalised approach recognises that Wegovy and Mounjaro equivalent doses represent starting points rather than fixed conversions, with ongoing adjustments based on individual treatment response.
Maximising Your Switch & Save Benefits with EverydayMeds
Take advantage of immediate savings by switching to Wegovy through EverydayMeds, starting with our comprehensive dose equivalence consultation. New customers receive additional value through discount code FIRST40, whilst our returning customer code DOSE25 ensures continued savings on future orders. Begin your treatment assessment today via our online portal, selecting the most appropriate bundle for your switching timeline - whether the Intro Trio for complete escalation or targeted Consistency bundles for maintenance doses. Our prescribers provide detailed switching guidance, ensuring optimal dose selection based on your previous treatment experience. Visit https://everydaymeds.co.uk/collections/weight-loss to start your clinical assessment and secure next-day delivery of your prescription-only medicine.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
